Metastatic Prostate Cancer Market: Epidemiology, Therapies, Companies, DelveInsight | AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Me

Metastatic Prostate Cancer therapies, such as NUBEQA (darolutamide), ERLEADA (apalutamide), MGC018 (vobramitamab duocarmazine), Bavdegalutamide (ARV-110), and others, are expected to boost the Metastatic Prostate Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Metastatic Prostate Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Metastatic Prostate Cancer, historical and forecasted epidemiology as well as the Metastatic Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Metastatic Prostate Cancer market report @ https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Metastatic Prostate Cancer Market Report:

In 2023, the metastatic castration-resistant prostate cancer (mCRPC) market across the seven major markets (7MM) was valued at approximately USD 7 billion, with projections indicating steady growth through 2034. The United States held the largest share of both the mCRPC (63%) and mCSPC (61%) markets within the 7MM, followed by the EU4 and the United Kingdom.
In March 2025, The FDA expanded the use of Pluvicto to treat adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received androgen receptor pathway inhibition and taxane-based chemotherapy.
In February 2025, the FDA awarded Fast Track designation to 67Cu-SAR-bisPSMA for treating PSMA-positive mCRPC in patients previously treated with androgen receptor pathway inhibitors. This designation facilitates the development of this innovative radiopharmaceutical.
Within the U.S., about 60% of prostate cancer cases were diagnosed at the localized or locally advanced stage, followed by those in the biochemical recurrence/progressive stage.
Despite the introduction of generic versions of ZYTIGA in the U.S. (2019) and Europe (late 2022), which significantly impacted revenue-particularly in the U.S.-the drug abiraterone acetate continues to be evaluated in combination with new and innovative therapies, helping it maintain a strong patient base.
XTANDI, from Janssen, remains the leading revenue-generating treatment in the prostate cancer market, continuing on a stable growth trajectory since 2021, even amid growing competition. Alongside XTANDI, ZYTIGA, and ERLEADA, Bayer's NUBEQA has emerged as a rapidly growing contender in the mCSPC segment. Bayer is aiming to expand NUBEQA's use, particularly in chemotherapy-ineligible patients, via the ongoing ARANOTE Phase III trial.
The mCRPC treatment landscape was notably enhanced by the FDA approval of Novartis' radioligand therapy, PLUVICTO, in 2022. This drug quickly gained traction in the third-line treatment setting, with Novartis planning to broaden its indication to include mHSPC by 2025.
In addition, PARP inhibitors are becoming increasingly important for patients with HRR gene mutations (such as BRCA1/2). Notable approvals in this space include AstraZeneca's LYNPARZA (first-line and beyond), RUBRACA (third-line), and recent 2023 approvals for TALZENNA, AKEEGA, and additional indications for LYNPARZA in the first-line setting.
The overall prostate cancer market, including both mCRPC and mHSPC, is expected to grow significantly. Key drivers include an aging population, increased disease awareness, expanded use of approved therapies, and the emergence of novel treatments.
According to estimates by DelveInsight, the total number of prevalent prostate cancer cases across the 7 major markets (7MM) reached approximately 8.24 million in 2023, with the figure expected to grow steadily from 2024 to 2034. The United States accounted for the largest share, reporting around 1.51 million diagnosed cases in 2023.
Multiple investigational therapies are currently in development by companies such as AstraZeneca (capivasertib), Arvinas (ARV-110), Daiichi Sankyo (D-7300), Essa Pharma (EPI-7386), and others, indicating continued innovation in this space.
In February 2025, Ibex Medical Analytics, a pioneer in AI-driven cancer diagnostics, obtained FDA 510(k) clearance for its Ibex Prostate Detect system. This in vitro diagnostic tool leverages artificial intelligence to produce heatmaps that help detect rare and subtle prostate cancers that might be overlooked, offering an additional layer of diagnostic support for pathologists.
In September 2024, Ipsen reported results from the Phase III CONTACT-02 trial, evaluating Cabometyx® in combination with atezolizumab for metastatic castration-resistant prostate cancer (mCRPC). While the study did not achieve a statistically significant improvement in overall survival, it successfully met its progression-free survival (PFS) target.
Also in September 2024, Foundation Medicine received FDA approval for its FoundationOne®CDx and FoundationOne®Liquid CDx tests to be used as companion diagnostics for Lynparza® in patients with BRCA-mutated mCRPC.
Key Metastatic Prostate Cancer companies such as AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others are evaluating new drugs for Metastatic Prostate Cancer to improve the treatment landscape.
Promising Metastatic Prostate Cancer therapies include NUBEQA (darolutamide), ERLEADA (apalutamide), MGC018 (vobramitamab duocarmazine), Bavdegalutamide (ARV-110), and others.

Metastatic Prostate Cancer Overview

Prostate cancer is a form of cancer that originates in the prostate gland, which is part of the male reproductive system. When the cancer spreads beyond the prostate to other parts of the body, it is referred to as metastatic prostate cancer or advanced prostate cancer. It most frequently metastasizes to lymph nodes or bones, but it can also reach other organs, such as the lungs.

Metastatic hormone-sensitive prostate cancer (mHSPC) refers to cases where the cancer has spread beyond the prostate but still responds to hormone therapy. On the other hand, metastatic castration-resistant prostate cancer (mCRPC) occurs when the cancer continues to progress despite hormone treatment.

Metastatic Prostate Cancer Market Outlook

Metastatic Castration-Resistant Prostate Cancer (mCRPC) is an advanced form of prostate cancer that has spread to other parts of the body-such as the lymph nodes or bones-and no longer responds to therapies that lower testosterone levels. Despite the availability of approved treatments, mCRPC remains a highly aggressive and ultimately fatal condition. Androgen deprivation therapy (ADT) is typically the first-line treatment for metastatic prostate cancer; however, most patients eventually progress to mCRPC and require additional systemic therapies, which can be difficult to manage.

Until 2010, docetaxel was the only treatment option shown to improve overall survival in mCRPC, gaining FDA approval in 2004 when combined with prednisone. For years, patients who progressed after docetaxel had few effective alternatives. In recent years, however, the treatment landscape has expanded with the approval of several new drugs, including JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, and AKEEGA.

Notably, PARP inhibitors have emerged as a major advancement. AKEEGA (Janssen), TALZENNA (Pfizer/Astellas), and LYNPARZA (AstraZeneca/Merck) were approved in 2023 for mCRPC, highlighting significant progress in targeted therapy for patients with specific genetic mutations.

Additionally, the approval of PLUVICTO has been a key milestone in treating advanced, treatment-resistant mCRPC. The therapy has demonstrated survival benefits and experienced a stronger-than-anticipated launch in the U.S. market.

Discover how the Metastatic Prostate Cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Metastatic Prostate Cancer Marketed Drugs
NUBEQA (darolutamide): Bayer
ERLEADA (apalutamide): Janssen

Metastatic Prostate Cancer Emerging Drugs
MGC018 (vobramitamab duocarmazine): MacroGenics
Bavdegalutamide (ARV-110): Arvinas

Scope of the Metastatic Prostate Cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Metastatic Prostate Cancer Companies: AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, AstraZeneca, Seagen/Merck, Bristol Myers Squibb, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis, and others
Key Metastatic Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), MGC018 (vobramitamab duocarmazine), Bavdegalutamide (ARV-110), and others.
Metastatic Prostate Cancer Therapeutic Assessment: Metastatic Prostate Cancer current marketed and Metastatic Prostate Cancer emerging therapies
Metastatic Prostate Cancer Market Dynamics: Metastatic Prostate Cancer market drivers and Metastatic Prostate Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Metastatic Prostate Cancer Unmet Needs, KOL's views, Analyst's views, Metastatic Prostate Cancer Market Access and Reimbursement

To know what's more in our Metastatic Prostate Cancer report, visit https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Metastatic Prostate Cancer Market Report:
Metastatic Prostate Cancer market report covers a descriptive overview and comprehensive insight of the Metastatic Prostate Cancer Epidemiology and Metastatic Prostate Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Metastatic Prostate Cancer market report provides insights into the current and emerging therapies.
The Metastatic Prostate Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Metastatic Prostate Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Metastatic Prostate Cancer market.

Got queries? Click here to know more about the Metastatic Prostate Cancer market Landscape https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Metastatic Prostate Cancer Patient Share (%) Overview at a Glance
5. Metastatic Prostate Cancer Market Overview at a Glance
6. Metastatic Prostate Cancer Disease Background and Overview
7. Metastatic Prostate Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Metastatic Prostate Cancer
9. Metastatic Prostate Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Metastatic Prostate Cancer Emerging Therapies
12. Metastatic Prostate Cancer Market Outlook
13. Country-Wise Metastatic Prostate Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Metastatic Prostate Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Metastatic Prostate Cancer Market Outlook 2034 https://www.delveinsight.com/report-store/metastatic-prostate-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Metastatic Prostate Cancer Pipeline Insights, DelveInsight

"Metastatic Prostate Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Prostate Cancer market. A detailed picture of the Metastatic Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Prostate Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.